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Abstract
           
Aims
            Cardiac arrest (CA) is an indication for defibrillator (ICD) implantation unless it occurs 
in the context of an acute myocardial infarction (AMI). We investigated the ventricular 
arrhythmia  (VA)-free survival of patients resuscitated  from CA in the setting  of AMI.
Methods
            We reviewed a database of 1600 AMI and CA survivors from which 48 patients were 
identified as having concurrent CA and AMI (CA+AMI group). Those patients were matched by 
age, gender, race, and left ventricular ejection fraction (LVEF) to 96 patients with AMI but no 
CA (AMI group) and 48 patients with CA but no AMI (CA group).                             
Results
            Patients and controls were followed for 3.9±3.2 years. Patients in the 3 groups had 
similar baseline characteristics (age 63±14 yrs, 78% men, 98% white, 53% with CAD, LVEF 
33±14%). The 5-year VA-free survival was 67%, 92%, and 80% for the CA+AMI, AMI, and 
CA groups, respectively,  p<0.001.                                                                            
Conclusions
            Patients with concurrent CA and AMI are at high risk of recurrent VA, with VA-free 
survival rates significantly worse than those of patients with AMI but no CA, and comparable to 
those of patients with CA outside the context of an AMI. Accordingly, these patients should be 
considered   for   ICD   implantation.                                                            
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Condensed   abstract                                                                      
            Patients with concurrent CA and AMI were found to be at high risk of recurrent VA, 
with VA-free survival rates significantly worse than those of patients with AMI but no CA, and 
comparable to those with CA only. Accordingly, these patients should be considered for ICD 
implantation.  
Key Words:  Cardiac Arrest, Ventricular Arrhythmias, Myocardial Infarction, Defibrillators, 
Mortality
Abbreviations
AMI      =    acute myocardial infarction
CA        =    cardiac arrest
CAD     =    coronary artery disease
HR        =    hazard ratio
ICD       =    implantable cardioverter-defibrillator
LVEF    =    left ventricular ejection fraction
VA        =    ventricular arrhythmia
            Cardiac arrest (CA) or hemodynamically compromising ventricular arrhythmias (VA) 
constitute an indication for defibrillator (ICD) implantation1-3 except when these life-threatening 
events occur in the context of acute myocardial infarction (AMI), which is considered a transient 
or reversible cause4. In fact, in this context, the implantation of an ICD is given a class III 
indication, i.e. it is considered not useful and potentially harmful4. There are however very few 
data to support these guidelines and recommendations.                                                     
            Data from the AVID registry5 suggest a high CA recurrence rates amongst survivors of 
CA whose events were felt to be associated with reversible causes such as myocardial ischemia 
or infarction. In the current era where ICDs are implanted for primary prevention purposes6-9, we 
designed this study to investigate the risk of recurrence of VA or death in survivors of CA in the 
context of AMI as compared to 2 control groups: survivors of AMI with no CA or VA (AMI 
group) and survivors of CA outside the context of an AMI (CA group).                       
Methods
Population
            All patients who were admitted to the University of Pittsburgh Medical Center with CA 
concurrent with AMI between 1992 and 2000 were included in this study. Patients electronic 
medical records were analyzed for baseline demographics, electrocardiographic data, clinical 
characteristics, left ventricular ejection fraction (LVEF), laboratory data both upon admission 
and discharge, admission and peak cardiac enzymes, inpatient medications and therapies, 
discharge medication, echocardiographic data, left and right heart catheterization data, ICD 
implantation and therapies, and associated medical conditions.                                             
            A total of 1600 records were reviewed, of which 48 consecutive patients with concurrent 
CA and AMI were identified. For each such patient, two controls with AMI but no CA and one 
with CA outside of the context of an AMI were identified and matched by age, gender, race and 
LVEF. A total of 192 patients were included in the analysis. All-cause mortality was obtained by 
reviewing medical records and by searching the National Social Security Death  Index10.  The 
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primary end points of the study was the time to death or first recurrence of sustained VA, 
defined as a VA requiring hospital evaluation, intervention, or appropriate ICD therapy. The 
study was reviewed and approved by the Internal Review Board of the University of Pittsburgh.
Statistical   analysis                                                                              
            Continuous variables were expressed as mean ± standard deviation and were compared 
using the student t-test. Categorical variables were compared using the Chi-square test. Times to 
event curves during the follow-up period were calculated by the Kaplan-Meier method and 
compared between groups using the log-rank tests. Multivariate analysis of the independent 
predictors of VA-free survival was performed using the Cox Proportional Hazards model. A 
two-tailed p-value of <0.05 was considered significant. All analyses were performed using SPSS 
14.0   version   (Chicago,   IL).                                                                              
Results
Demographic data                                                                                                   
            A total of 48 consecutive patients were admitted to the University of Pittsburgh Medical 
Center with concurrent CA and AMI. They were matched to 96 control patients with AMI but no 
CA and to 48 control patients with CA outside the context of an AMI. Cases and controls were 
followed at our institution for a mean duration of 3.9±3.2 years. The demographic and clinical 
characteristics of patients and controls are shown in Table 1. 
            Compared to the patients in the AMI group, patients in the CA+AMI group were more 
likely to have a history of coronary artery disease (56.3% vs.36.5%, p=0.018), of CA (8.3% vs. 
0%, p=0.004), and atrial fibrillation (25% vs. 3.1%, p<0.001). Compared to patients in the CA 
group, cases (CA+AMI group) were less likely to have a history of cardiomyopathy (20.8% vs. 
58.3%, p=0.001). Also, the use of β-blockers, Angiotensin converting enzyme inhibitors, and 
anti-arrhythmic medications were higher in the survivors of concurrent CA and AMI compared 
to   the   patients   in   the   control   groups.                                                    
            As expected based on published guidelines4, there was a large discrepancy (p<0.001) in 
the use of ICD therapy between the 3 study groups, with the survivors of CA outside the context 
of AMI having the highest rates (98%), followed by survivors of concurrent CA and AMI 
(73%), followed last by survivors of AMI without CA (7%). It is worth noting that based on the 
most recent guidelines, which state that patients with LVEF35% are indicated for ICD 
implantation, 56 of 96 (58%) patients in the AMI group and 29 of 48 (60%) patients in the CA
+AMI group would qualify for ICD implantation.                                                               
               At the time of admission to the hospital,  there was evidence on the surface 
electrocardiogram of ST segment elevation AMI in 16 of 48 (33.3%) patients in the concurrent 
CA+AMI group compared to 52 of 96 (54.2%) in the AMI group (p=0.014). Of the 144 patients 
in the CA+AMI and AMI groups, 33 (16%) underwent revascularization (12 by percutaneous 
coronary intervention and 11 by coronary artery bypass grafting) at the time of the index 
hospitalization or during follow-up.
Time to Death or First Ventricular Arrhythmia                                                                           
            We compared the time to death or first VA in the 3 patient study groups. Patients in the 
CA+AMI group had lower VA-free survival compared to patients in the control groups (5-year 
VA-free survival of 67%, 92%, and 80% for patients in the CA+AMI,  AMI,  and CA  groups 
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 8(1): 5-13 (2008)Ish Singla, Haitham Hreybe, Samir Saba,  “Risk of Death and Recurrent                    8 
Ventricular Arrhythmias in Survivors of Cardiac Arrest Concurrent With Acute Myocardial 
Infarction”
respectively, p<0.001). Kaplan Meier curves were constructed to reflect the VA-free survival 
over the mean follow-up period of 3.9±3.2 years and are shown in Figure 1.
Table 1. General demographic and clinical characteristics of the study population.
CA=cardiac arrest; AMI=acute myocardial infarction; CRI=chronic renal insufficiency; COPD=chronic obstructive 
pulmonary disease; CAD=coronary artery disease; AF=atrial fibrillation; LVEF=left ventricular ejection fraction; 
CK-MB=creatinine kinase-MB fraction; CK-RI= creatinine kinase-risk index; STEMI=ST segment elevation 
myocardial infarction; PCI/CABG=percutaneous coronary intervention/coronary artery bypass grafting; ACE 
I=angiotensin   converting   enzyme   inhibitor;   AAD=anti-arrhythmic   drug;   ICD=Implantable   Cardioverter-
defibrillator. (*) p≤ 0.05 for comparisons with the CA+AMI group of patients.
            The VA-free survival was analyzed in a multivariate Cox Regression model adjusting for 
such covariates as age, LVEF, QRS width, cardiac rhythm documented at the time of hospital 
admission, and implementation of therapies such as coronary revascularization, use of β-
blockers, use of anti-arrhythmic drugs, and defibrillator implantation. After adjusting for all 
these covariates, patients with concurrent CA and AMI remained at a higher risk compared to 
the 2 control groups for death or recurrent VA (Hazard Ratio, HR=3.3, 95% confidence interval 
=1.4-8.1,   adjusted   p=0.008).                                                                      
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          Figure 1.Time to death or first ventricular arrhythmia by study group
Incidence of Ventricular Arrhythmia   
            Patients with concurrent CA and AMI also had a higher incidence of VA when compared 
to patients with CA without AMI and patients with AMI without CA. The incidence of VA 
recurrence over the follow-up period was 57%, 40% and 11% in the CA+AMI, CA, and AMI 
groups, respectively (p<0.001). The incidence of VA among the 3 study groups is shown in 
Figure 2.
Figure 2. Incidence of death or ventricular arrhythmia by study group
    The risk of VA was also analyzed using a multivariate binary logistic regression model. After 
correcting for age, LVEF, QRS width, cardiac rhythm documented at hospital admission, 
coronary   revascularization,  utilization   of   β-blockers,   anti-arrhythmic   drugs,  and   ICD 
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implantation, patients with concurrent CA and AMI remained at a higher risk for VA recurrence 
(HR=5.1, 95% confidence interval =1.4-19.1, adjusted p=0.015).                                               
Time to Death Among Study Groups and Effect of Appropriate ICD Therapy                        
            We analyzed the time to death in the 3 study groups. In the overall cohort, there was no 
difference in survival (p=0.75, Figure 3a). Because a large proportion of patients in our study 
had defibrillators and given the established mortality benefits conferred by the ICD, we 
conducted analysis on the cumulative incidence of appropriate ICD therapies, defined as ICD 
shocks or anti-tachycardia pacing events for treatment of VA, in the subgroup of patients who 
had an ICD (73%, 7%, and 98% of patients  in the CA+AMI, AMI, and CA groups, 
respectively). The total number of patients implanted with an ICD was 89 (46% of the overall 
population). As shown in Figure 3b, the time to first appropriate ICD therapy was significantly 
shorter in the group of patients with concurrent CA and AMI or CA alone compared to the AMI 
group (2-year cumulative incidence of appropriate ICD therapy of 36%, 34%, and 0% for the 
CA+AMI, CA, and AMI groups respectively, p<0.001).                                    
Discussion
            Our data demonstrate that patients with concurrent CA and AMI are at significantly 
increased risk of death or recurrent VA compared to patients with AMI and no associated CA. 
Also, their risk exceeds that of patients with CA outside the immediate context of an AMI, a 
population that has an established indication  for ICD implantation according to current 
published guidelines4 which are based on a number of large, randomized, prospective trials1-3. 
This finding is consistent with prior published data5,11 where patients with reversible causes of 
CA or VA were found to have a high mortality rate comparable to that of patients randomized to 
the control (no ICD) arm in the AVID trial1. Although there was no difference in total mortality 
between the 3 groups in our study, this is probably accounted for by the difference in ICD 
implantation and appropriate ICD therapy delivered amongst the 3 groups. Although not every 
shock translates into a life saved12, almost every life saved by a defibrillator is from an 
appropriate ICD therapy. This is a plausible statement, given the documented mode of death in 
survivors of CA who do not receive an ICD1 and given the intrinsic mode of function of the 
ICD. 
               While current guidelines support the implantation of an ICD for patients with 
cardiomyopathy on the basis of persistently depressed left ventricular function and even in the 
absence of previous arrhythmic events8,9, survivors of concurrent CA and AMI do not qualify for 
ICD therapy4. Our study suggests that patients with concurrent CA and AMI are at a similar 
mortality risk and at a higher risk for recurrent VA compared to CA survivors. Hence, ICD 
implantation among this patient population should be considered. Also, with the expanding 
indications for ICD implantation for primary prevention6-9, many survivors of CA in the context 
of an AMI would have an indication for ICD implantation anyway, albeit few months after the 
event. This fact may need to be factored into the decision making about early ICD implantation, 
prior to hospital discharge.
            Some studies13 have questioned the value of the ICD implantation early after AMI. The 
DINAMIT study13 demonstrated that early ICD therapy is associated with a reduction in the rate 
of arrhythmic deaths but that this benefit was offset by an increase in the rate of death from non-
arrhythmic causes.  It is important however to keep in mind the fact that DINAMIT enrolled 
patients whose ICDs were implanted for primary prevention purposes as opposed to our current 
study which deals with survivors of a CA. Even in the context of primary prevention, the risks of 
waiting before implanting an ICD is challenged by the high risk of CA early after AMI that has 
been demonstrated in the VALIANT study14.
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Figure 3a. Time to death by study group
Figure 3b. Cumulative incidence of appropriate ICD therapy by study group
            Mechanistically, denying a life-saving therapy such as the ICD to patients with reversible 
causes of VA or CA is flawed for 2 reasons. First, patients who suffer a CA secondary to 
presumed reversible causes such as ischemia, myocardial injury, or electrolyte imbalances are at 
continued risk of recurring episodes of such reversible, albeit not avoidable, events. Second, The 
CA that happens secondary to a reversible cause may just reflect an underlying predisposition, 
genetic or other, in the survivor of such event i.e. a different trigger in the same subject may lead 
to a future CA because of a lower fibrillation threshold that the patient may have. Although 
speculative, these concerns are very plausible and have to be considered before denying a patient 
an ICD implantation because their CA was concurrent with an AMI.                                 
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            Our study has some limitations. First, the data was collected retrospectively and therefore 
its accuracy depends on the accuracy of the electronic medical records and clinical charts. Some 
patients who are not currently followed at our institution might have had VA after they were lost 
to follow-up, which could not be accounted for. In addition, patient compliance with standard 
medical therapy after hospital discharge could not be ascertained. Second, our study was a single 
center   study   with   a   moderate   number   of   patients   who   were   mainly   male   Caucasians. 
Extrapolating our results to other patient populations from different ethnic or geographic 
backgrounds   may   not   be   attainable.                                                        
            In summary, our data suggests that survivors of concurrent CA and AMI are at high risk 
for death and recurrent VA. While in the current guidelines these patients are denied ICD 
implantation, our study suggests that they may benefit from this life-saving therapy. Further 
prospective, randomized studies are however needed to establish the potential effect of the ICD 
on the overall mortality of survivors of concurrent CA and AMI before the current guidelines 
may be revised.
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